Atorvastatin Superior To Other Statins?

23 April 1995

Parke-Davis' HMG-CoA reductase inhibitor atorvastatin has outperformed other statin drugs in head-to-head comparative studies, according to company chairman Ronald Cresswell at an analysts' briefing in New York, USA.

Atorvastatin, at a dose of 10mg, is more effective in reducing serum lipids than all the other available statins at their highest approved doses, said Dr Cresswell. The drug lowers low-density lipoprotein cholesterol by as much as 60%, triglycerides by as much as 40%, and raises beneficial high-density lipoprotein cholesterol by around 12%.

Dr Cresswell predicted that a New Drug Application for atorvastatin would be filed in the middle of next year, and the company hopes to achieve sales of $800 million a year at peak. The company expects to build on the lipid-lowering franchise it has achieved with its Lopid (gemfibrozil) range of products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight